Title: Glia-specific autophagy dysfunction in ALS

Author names and affiliations:

Laura Strohm^a, Christian Behrends^a

^a Munich Cluster for Systems Neurology, Medical Faculty, Ludwig–Maximilians–Universität München, Munich, Germany

Christian Behrends Corresponding author at: Munich Cluster for Systems Neurology, Medical Faculty, Ludwig– Maximilians–Universität München, Munich, Germany christian.behrends@mail03.med.uni-muenchen.de

Postal Address: Munich Cluster for Systems Neurology (SyNergy) Ludwig-Maximilians-Universität (LMU) München Feodor-Lynen Strasse 17 81377 München **Germany**

Keywords: autophagy; neurodegeneration; amyotrophic lateral sclerosis; frontotemporal dementia; microglia; oligodendrocyte; astrocyte; glia; inflammation

Abstract

Neuronal cell death is the main pathological feature of chronic neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). As age is strongly linked to NDs, these diseases are one of the leading medical and societal challenges faced by the rapidly aging western societies. Despite the increasing prevalence, the causes and mechanisms behind most NDs are still vague. A common hallmark of several NDs is the accumulation and aggregation of proteins. Prominent examples are amyloid beta and tau in Alzheimer's disease, α -synuclein in Parkinson's disease and transactive response DNA binding protein 43 kDa (TDP-43) in ALS and FTD. Under physiological conditions, protein quality control systems, namely the ubiquitin proteasome system and the autophagy machinery, eliminate such aberrant protein forms and thereby prevent proteotoxic stress. However, as proteins must unfold to undergo proteasomal degradation, aggregated proteins are poor substrates for the proteasome. Such proteins are thought to be primarily turned over by autophagy. Therefore, autophagy is considered a critical ND-protective pathway, which opens up potential new therapeutic interventions. One drawback is that the majority of research in NDs has been focused on elucidating the underlying pathomechanisms in neurons. However, neurons make up only about half of the brain cells with neuroglia being the other major central nervous system (CNS) cell type. Due to the ubiquitous presence of disease-causing mutations in all cells of the CNS, it is likely that non-neuronal cells contribute to the disease onset and/or progression. While our understanding of the roles of autophagy and its contribution to neurodegeneration in neurons deepened considerably over the last years, still comparatively little is known about the functions and disease contribution of the autophagy machinery in glia cells.

1. Autophagic Pathways

Autophagy, Greek for "self-eating", is a highly conserved recycling process, which is present in all eukaryotes [1]. This term describes the delivery of cytosolic material to the lysosome and its subsequent lysosomal degradation. Three different autophagic pathways (microautophagy, chaperone-mediated autophagy (CMA) and macroautophagy) are distinguished in mammals based on the delivery mode of the cargo to the lysosome. In microautophagy smaller portions of cytoplasm are invaginated into the lysosomal membrane, which then pinch off inwards as vesicles. In contrast to this mainly unselective pathway stands the highly selective CMA. Chaperones recognize specific substrate proteins and shuttle them to the lysosome where they are unfolded and translocated through the membrane. During macroautophagy endogenous or exogenous cytosolic material is engaged by a cup-shaped membrane (coined phagophore) that expands to surround the cargo entirely. Membrane closure results in the formation of autophagosomes, which deliver their content for bulk degradation upon fusion with lysosomes [2-4] (Figure 1). Depending on the cellular condition, macroautophagy can degrade vast portions of the cytosol or exclusively target selective constituents of the cytoplasm. Since macroautophagy (referred to as autophagy hereafter) is by far the most studied autophagic pathway in the context of glia cells, we focus on this process.

1.1. Autophagy Machinery and Regulation

The formation of autophagosomes is tightly controlled by autophagy-related (ATG) proteins. While most cell types exhibit basal levels of autophagy, stress stimuli such as nutrient or growth factor deprivation, hypoxia, DNA damage or protein aggregates can further activate autophagy [5]. For example, aminoacid deprivation leads to an inactivation of the target of rapamycin 1 complex (TORC1) kinase and allows its substrate ATG13 to be rapidly dephosphorylated [6]. This induces the assembly of the unc-51-like kinase 1 (ULK1) and ULK2 complex at the endoplasmic reticulum (ER). In addition to ULK1 and ULK2, this complex consists of ATG13, ATG101 and RB1-inducible coiled-coil protein 1 (RB1CC1) and coordinates the recruitment of other initiation factors including ATG9 vesicles and the autophagy specific class III phosphatidylinositol 3-kinase (PI3K-III) complex [7, 8]. ULK-dependent phosphorylation of the PI3K-III complex, which is composed of the subunits PIK3C3, PIK3R4, BECN1 and ATG14, in turn induces the generation of phosphatidylinositol 3-phosphate (PI3P). As a result, a PI3P-enriched domain of the ER is formed which morphologically resembles the Greek letter omega and has thus been termed omegasome [9]. PI3P-binding proteins including the zinc-finger FYVE domain-containing protein 1

(DFCP1) and WD repeat domain phosphoinositide-interacting protein 2 (WIPI2) are subsequently recruited to these specialized ER domains and direct the conjugation of the ubiquitin (Ub)-like human ATG8 proteins to phosphatidylethanolamine incorporated in the phagophore membrane [10, 11]. Exactly how phagophores emerge from such omegasomes is less well understood. A central question is the origin of the autophagosomal membrane. Recent data suggest that next to the ER, mitochondria, the Golgi apparatus and the plasma membrane contribute lipids to the phagophore [10, 12-14]}. On the molecular level, the ATG8 conjugation machinery controls the phagophore expansion. This machinery comprises the E1 activating enzyme ATG7, the E2 conjugating enzyme ATG3 and the E3 ligase scaffolding ATG12–ATG5-Atg16L1 complex [15, 16]. Human cells contain six ATG8 family members that can be grouped into two subfamilies: i) microtubule-associated proteins 1A/1B light chain 3A (LC3A), LC3B and LC3C and ii) γ-aminobutyric acid receptor-associated protein (GABARAP), GABARAPL1 and GABARAPL2 [17]. While the subfamily of LC3 proteins has been demonstrated to act early in phagophore expansion, GABARAP proteins were implicated later in autophagosome closure and maturation [18]. ATG8-PE conjugates are incorporated into the inner and outer surface of autophagosomes where ATG8 provides a docking site for cargo receptors and regulatory adaptor proteins. While the former facilitate delivery of autophagosomal cargo to lysosomes, the latter contribute to autophagosome assembly and maturation as well as transport and lysosomal fusion. Furthermore, inner-leaflet ATG8 remains a part of the autophagosome through the whole process of its formation and maturation and is finally degraded in the lysosome, whereas ATG8 molecules conjugated to the outer autophagosome membrane are cleaved off by protease ATG4. The scission of the extremities of the growing phagophore results in a completed and closed double-layered autophagosome [19]. Finally, the fusion of autophagosomes with lysosomes results in autolysosomes and the subsequent cargo degradation [20-22].

1.2. Bulk versus Selective Autophagy

Autophagy is an essential process due to divers, indispensable functions. Initially, it was described as a catabolic pathway with the purpose of providing new building blocks through turnover of cellular constituents [23-25]. Cells are in constant need of a pool of metabolites to be able to generate new proteins, lipids and carbohydrates. If this pool cannot be replenished from extracellular sources, cells need to compensate for the lack of these nutrients. Therefore, cells have sensors, which continuously monitor metabolic stress levels to sense for example nutrient and energy deficits. The three central sensing pathways include sirtuin 1 (SIRT1), AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR). SIRT1 and AMPK sense changes in intracellular NAD⁺ and AMP levels, respectively [26]. The master regulator mTOR processes nutrients, growth factors, energy and stress inputs, partially by integrating AMPK and SIRT1 signals [27]. As a consequence, these sensors activate autophagy in metabolic stress periods. Since under these conditions it is the highest priority to overcome starvation, any cytoplasmic material is rather non-selectively degraded by so called bulk autophagy.

On the other hand, autophagy also plays a major role in the cellular quantity and quality control by degrading surplus or damaged organelles (e.g. mitophagy), aberrant or aggregated proteins (aggrephagy) as well as cytosol-invading pathogens (xenophagy) [28-30]. These selective forms of autophagy are characterized by the labelling of the cargo with specific "eat-me" signals, which are then recognized by autophagic receptors. The most prominent "eat-me" signal is Ub, which is for example conjugated to proteins within aggregates or outer mitochondrial membranes by different ubiquitination machineries. Additionally, lipid and sugar moieties that accumulate on the organelle surface are also able to function as autophagic degrons [29, 31]. Autophagy receptors recognize these signals with the help of degron-specific domains such as Ub-binding domains (UBD) in the case of Ub and physically link the bound cargo to the nascent autophagosome through interaction with members of the ATG8 family. This latter interaction is mediated by a short linear sequence with the consensus motif $F/W/Y_{1-}$ X_2-X_3 -I/L/V₄ (where X can be any amino acid) known as LIR (LC3-interaction region) or AIM (ATG8 family-interacting motif) which is common to all autophagy receptors and that non-covalently engages a highly conserved binding site on ATG8 family proteins [32, 33]. Several UBD-containing autophagy receptors exist, namely Sequestosome-1 (SQSTM1, also known as p62), next to BRCA1 gene 1 protein (NBR1), Calcium-binding and coiled-coil domain-containing protein 2 (CALCOCO2, also known as nuclear dot protein 52 (NDP52)), Optineurin (OPTN), Tax1-binding protein 1 (TAX1BP1) and Tollinteracting protein (TOLLIP). To what extend these receptors are functionally redundant or act synergistically in the distinct Ub-dependent selective autophagy pathways is not fully understood.

1.3. Extended Functions of the Autophagy Machinery: More than Degradation

Besides the quantity and quality control functions of autophagy, autophagy-related processes recently moved into the spotlight. These processes involve parts of the autophagic machinery but either the formation of autophagosome or the lysosomal degradation of cytosolic constituents is absent. So far, it was shown that ATG proteins play inter alia roles in cell survival, apoptosis, signaling, cellular transport and secretion [34]. A relatively well-described autophagy-related pathway known as secretory autophagy mediates the unconventional secretion of leaderless proteins under certain stress conditions. Proteins, which lack a signal for entering the conventional ER-Golgi-membrane pathway are exported outside the cell via translocation across the membrane of an autophagosome-like vesicular intermediate which eventually fuses with the plasma membrane [35-37]. Another example of an autophagy-related process is autophagic cell death. Although autophagy is known to block the induction of apoptosis, it is substantiated that autophagy is also able to activate cell death. Here, the autophagosomal membrane serves as a scaffold for the assembly of the intracellular death-inducing signaling complex mediating for instance the activation of caspase-8 and thereby the initiation of the apoptotic cascade [38, 39].

2. Roles of Autophagy in Different CNS Specific Cell Types

In 1856, R. Virchow described a cell population in the brain, distinct from neurons, which he believed functions to embed the neurons and to hold everything together. Therefore he named them "Neuroglia", according to the ancient Greek word "glia" for glue. More than 50 years later, Río-Hortega firstly distinguished between the three main glial cell types: microglia, astrocytes and oligodendrocytes. Nowadays, it is known that glia are far more than only bystanders and cement of neurons. Their functions in tissue homeostasis, myelin formation, development regulation and synaptic communication are broadly known. With the appreciation of their fundamental roles in the CNS, it became clear that they are likely important players in disease states as well. Defective autophagy is thought to contribute to neuronal degeneration and to the development of NDs. Therefore, we wanted to review the roles of autophagy in glia cells during neurodegeneration, exemplified for ALS and FTD.

2.1. ALS and FTD

ALS is the most common adult-onset motor neuron disease with degeneration of upper and lower motor neurons. This disease is characterized by rapid progression of muscle weakness, which leads to death within one to five years after diagnosis. Often ALS patients also present cognitive changes ranging from mild abnormalities to severe FTD [40], which comprises a group of disorders caused by a more widespread cortical affection, which results in cognitive and language deficits or changes in personality and behavior [41]. Despite the distinct neurological and psychiatric symptoms, ALS and FTD are tightly linked by shared neuropathological markers (i.e. RNA-binding protein TDP-43-positive inclusions) [41, 42] and mutations in common genes [43, 44]. Approximately 10% of all ALS cases are familial and 90% are sporadic. While the molecular basis of ALS and FTD remains largely unknown, many ALS-causing genes are directly or indirectly connected to autophagy (Figure 2). Some of them function in distinct or even multiple steps of the autophagy pathway whereas for others this is not formally established. Still, a rough classification is possible for several ALS genes. Optineurin (OPTN), ubiquilin-2 (UBQLN2) and SQSTM1 are known autophagy receptors, while the TANK-binding kinase 1 (TBK1), the Rab guanine nucleotide exchange C9ORF72, the Ub E3 ligase substrate adaptor cyclin F (CCNF), the Rho guanine nucleotide exchange factor ALS2 and the vesicle-associated membrane protein-associated protein B/C (VAPB) are associated with autophagy regulation and initiation [45-56]. TAR DNA binding protein (TDP-43) and the multifunctional AAA-type ATPase valosin-containing protein (VCP, alias p97) have functions in autophagosome maturation [57, 58]. Furthermore, charged multivesicular body protein 2b (CHMP2B), ALS2, phosphoinositide phosphatase (FIG4), 1-phosphatidylinositol 3-phosphate 5-kinase (PIKFYVE) and VCP have functions in autophagosome-lysosome fusion and cytoplasmic dynein 1 intermediate chain 1 (DCTN1) in the transport of autophagosomes [59-65]. In addition, the ALS gene spatacsin (SPG11) was observed to play a role in lysosome reformation [66]. Importantly, mutated superoxide

dismutase 1 (SOD1) and RNA-binding protein fused in sarcoma (FUS), which can be found in ALSassociated inclusions, are also known to interfere with several events in autophagy [53, 67, 68]. However, how the aggregates formed in ALS affect the autophagic pathway have been acquired using (motor)neuronal cells and data from glia cells are lacking. ALS mutations are mostly inherited in an autosomal-dominant manner [69] and range from point mutations (in all genes except C9ORF72), frame shifts (e.g. in OPTN) to GGGGCC (G_4C_2) hexanucleotide repeat expansions in a non-coding region (C9ORF72). For most of these genes it remains to be determined if the underlying disease mechanism is due to loss of function, gain of one or more toxic properties or both. Expanded C9ORF72 G4C2 repeats, which are most often found in ALS/FTD patients, are an example for the latter as haploinsufficiency, aberrant RNA interactions and production of toxic translation products (dipeptide repeat proteins; DRPs) and aggregates have been suggested as non-mutually exclusive toxicity mechanisms [70]. Evidently, defective autophagy plays a crucial role in ALS/FTD and inclusion bodies in motor neurons are considered a pathological hallmark of ALS. However, protein aggregates are also present in astrocytes, microglia and oligodendrocytes of ALS patients [71-73].These observations together with several studies showing non-cell autonomous mechanisms in ALS/FTD, indicate the involvement of defective glial autophagy in the disease [74-79].

2.2.Microglia

2.2.1. General Functions of Microglia

Microglia are the immunocompetent cells of the CNS and account to 10-15% of its cells. They originate from a pool of primitive macrophages derived from the embryonic yolk sac, which proliferate in the brain and maintain themselves by local self-renewal. Adult microglia are equally distributed throughout the brain and the spinal cord [80-82]. The main functions of microglia include synaptic pruning during development, regulation of synaptic activity, neurogenesis and immune response [83]. Homeostatic microglia have a ramified appearance with branches and processes with which they constantly screen their environment for example by contacting neurons, astrocytes and blood vessels [84]. Various microglial receptors such as neurotransmitters and immune receptors are essential for this surveillance function [85-88]. Disturbances in tissue homeostasis are registered by these receptors whereupon microglia shift from their homeostatic state to a disease associated state [89]. Concurrently, microglia acquire an amoeboid shape, proliferate and migrate towards the origin of the disturbances. Microglial activation can be accompanied by production of neurotoxic, excitatory and pro-inflammatory signals (i.e. cytokines, chemokines and reactive oxygen species (ROS)), generation of anti-inflammatory cues, activation of adaptive immunity and phagocytosis of apoptotic cells, pathogens, extracellular protein aggregates and other cell debris. Although the classical distinction between a proinflammatory M1 phenotype and an anti-inflammatory M2 phenotype is still common, recent technical advances in singlecell sequencing in fact revealed a variety of microglial gene expression profiles in different physiological or pathological conditions which likely reflects a spectrum of different microglial states [90, 91].

2.2.2. Autophagic Functions in Microglia

Autophagy participates in the regulation and the execution of innate as well as adaptive immune responses. Autophagy can be activated by pattern recognition receptors (PRRs), which recognize pathogen-associated molecule patterns (PAMPs) and damage-associated molecule patterns (DAMPS). Upon detections of pathogens or other exogenous ligands by PAMPs/DAMPs, autophagy is activated followed by the elimination of intracellular pathogens [92-94]. This has been demonstrated for example for toll-like receptor 7 (TLR7) in macrophages [95]. Furthermore, autophagy operates as a topological inverter which ferries cytosolic antigens into the lumen of major histocompatibility complex (MHC)-II compartments for antigen presentation [96, 97]. On the inflammasome, autophagy has a two-sided effect. On the one side, autophagy restricts inflammasome activation. Saitoh *et al.* have shown that deletion of the autophagy protein ATG16L1 results in increased levels of proinflammatory, endotoxininduced interleukin (IL-1 β) in murine fetal liver macrophages. By the removal of damaged mitochondria, autophagy prevents the accumulation of cytosolic mitochondrial DNA and overproduction ROS, thus preventing inflammasome activation [98-101]. Houtman *et al*. observed an increase of IL-1b and IL-18 in neonatal primary microglia with as well genetic as chemical induced defects in autophagy. They show

evidence indicating that Family Pyrin Domain Containing 3 (NLRP3), the PRR of the NLRP3 inflammasome, is degraded by autophagy and thereby provide another mechanism explaining the connection between autophagy and the inflammatory response. On the other side, autophagy controls IL-1b and IL-18 activation, release and signaling by contributing to its biogenesis and unconventional secretion [102, 103] (Figure 3). However, beside autophagy mediated IL-1 β secretion, pyroptosis, a form of osmotic cell death, and pore-forming protein Gasdermin D-dependent secretion are in the focus of recent studies [104, 105]. Furthermore, in 2011 it was described by Harris *et al*. that autophagy also negatively regulates IL-1 β secretion by degrading pro-IL-1 β [106]. More recent data present contradictory results, showing that pro-IL-1 β is rather degraded by the proteasome than by autophagy [107, 108]. Eldrige *et al*. determined the ubiquitin E2 enzyme UBE2L3 as a regulator of pro-IL-1b protein levels in human and murine cells. UBE2L3 promotes the ubiquitylation and thereby the proteosomal degradation of pro-IL-1 β . UBE2L3 itself is indirectly targeted for degradation by caspase-1, Therefore, an increase of IL-1 β after autophagy inhibition is possibly mediated by the reduction of the inflammasome and the subsequent increase of UBE2L3.Based on the various roles of autophagy in microglia, it is expected that mutations in autophagy genes linked to ALS not only affect neuronal health but also impact on the functionality of microglia.

Box: Inflammasome

Inflammasomes are a group of cytosolic multimeric protein complexes which form molecular platforms. A typical inflammasome consists of specific pattern recognition receptors (PRRs), which are connected to inflammatory caspases via adaptor proteins. The PRRs sense pathogenic insults resulting in the cleavage and activation of the inflammatory caspases. These activated caspases in turn induce proteolytic cleavage of pro-inflammatory cytokines into their mature form and their secretion, which induces an inflammatory response [109, 110].

2.2.3. Microglial Autophagy in ALS

Neuroinflammation is known to play an important role in ALS with more than thousand inflammatory genes differentially expressed in ALS patients compared to healthy control individuals [111]. Moreover, it was shown that microglia reactivity precedes symptom onset in SOD1 transgenic mice and that disease progression is accompanied by microgliosis in patient brain sections [112-114]. Accordingly, transplanted wild-type microglia are able to slow down disease progression in ALS transgenic animals [115]. In line with the immunological pathogenesis tumor necrosis factor alpha (TNF α) levels are elevated in ALS patients [116-118]. A recent study by Jin *et al*. reported decreased autophagic flux in microglia upon $\text{TNF}\alpha$ exposure. Concomitantly, an elevation of pro-inflammatory markers was observed, suggesting that downregulation of autophagy in murine BV2 microglia cells leads to increased neurotoxicity [119]. This finding was substantiated by the observation that activation of autophagy in BV2 cells led to a reduction of lipopolysaccharides (LPS) or α -synuclein induced pro-inflammation [120]. Recently, Yoon and colleagues demonstrated the importance of autophagy in microglia for synaptic homeostasis and proper synaptic function in mice [121] (Figure 3). Therefore, impaired autophagy in microglia could at least partially contribute to the observed synaptic abnormalities in motor neurons of ALS patients. Furthermore, a C9orf72 loss of function study emphasized the role of autophagy in microglia in ALS. Intriguingly, deletion of C9orf72 in mice did not lead to a motor neuron phenotype but instead gave rise to lysosomal accumulation and altered immune response in microglia [122]. In contrast, loss of motor neurons has been shown in several C9orf72 loss-of function and gain-of function models [49, 51, 71, 123-125]. Interestingly, a number of laboratories independently reported that C9orf72 functions in different steps of the autophagy pathway in conjunction with SMCR8 and WDR41 [49, 50, 126, 127]. However, it is still unclear whether defective autophagy caused for example by C9orf72 haploinsufficiency is a primary cause of ALS or a modulator of the disease phenotype. Overexpression of a mutated form of SOD1 in microglia gave further insight into the role of autophagy in microglia during ALS. In this study, primary rat microglia accumulated SOD1, displayed impaired autophagy, shifted to an activated phenotype and induced neurotoxicity in co-cultures with neurons [78]. Together, there is increasing evidence that defective autophagy in microglia contributes to ALS pathogenesis, most likely through changes in microglial inflammasome activation and protein clearance.

2.3.Astrocytes

2.3.1. General Function of Astrocytes

Astrocytes were first mentioned by Lenhossek in 1891 and include all cells which match the characteristics of star-like cells with numerous fibrils in their cytoplasm. As a result, astrocytes present the most diverse cell population in the CNS. They are divided into two main subtypes: protoplasmic astrocytes, found in the grey matter, and fibrous astrocytes, which are located in the white matter. Interestingly, astrocytes are organized in separate spatial domains, which do not overlap under physiological conditions [128, 129]. Astrocytes are found in close proximity of blood vessels and their processes often envelop synapses [130]. This location allows inference on their function. They cover blood stream regulation, modulation of synaptic function, neurotransmitter recycling as well as provision of trophic, antioxidant and metabolic support to neurons [131-134] (Figure 3). Astrocytes are able to release transmitter precursors and transmitters, purines, growth factors, and energy substrates like lactate. For example, in response to glutamate release by neurons, astrocytes increase their glucose utilization and provide lactate to neurons to fuel their metabolism [135, 136]. Astrocytes are able to enhance their glucose uptake from blood vessels or to break down their glycogen granules and generate lactate [137, 138]. Although astrocytes are non-excitable cells, they express ion channels and neurotransmitter receptors and exhibit a $Ca²⁺$ based "intrinsic excitability" [139-141]. Due to these properties, they can serve to clear transmitters from the synaptic space in order to prevent their extrasynaptic accumulation and consequential excitotoxicity [142-144]. In a similar manner, astrocytes regulate ion homeostasis in the synaptic space [145]. Furthermore, the detection of synaptic activity induces an elevation of $Ca²⁺$ in astrocytes, resulting in the release of synaptically active molecules such as glutamate, d-serine and adenosine triphosphate (ATP) from these astrocytes. These so-called gliotransmitters in turn allow feedback regulation of neuronal activity and synaptic strength by acting on neuronal receptors [146, 147]. In addition, astrocytes are active players in neuroinflammation. They have the capability to secret a wide range of pro- and anti-inflammatory chemokines and cytokines, including TNFα, IL-6, IL-10 and CC-chemokine ligand 2 [148-151]. The central role of astrocytes in the regulation of neuroinflammation was further substantiated by *in vivo* data of mice with inhibited NF-kB in astrocytes [152, 153]. In response to any forms of CNS insult, astrocytes change their morphology, function and molecular profile in a highly graduated continuum, referred to as reactive astrogliosis [154- 156]. Astrogliosis is defined by upregulation of intermediate filaments, mainly glial fibrillary acidic protein (GFAP), vimentin and nestin, and by cellular hypertrophy [157]. Besides, reactive astrocytes have elevated phagocytic capacity [158-161]. Severe astrogliosis additionally comprises proliferation, leads to disruption of individual spatial domains, and causes inflammation and glial scar formation [162-164]. Taken together, astrocytes are key for CNS homeostasis due to their comprehensive roles. However, in disease states the beneficial functions of astrocytes can revert to detrimental effects.

2.3.2. Autophagic Functions in Astrocytes

In contrast to the recent advances in the understanding of autophagic functions in microglia, still relatively little is known about its role in astrocytes. Based on the widespread functions of astrocytes especially in the uptake and release of molecules as well as in immune reactions, it seems plausible that autophagy likewise exerts crucial functions in these cells. However, support for this notion is only anecdotal. For example, given that astrocytes have the capacity to phagocyte and to secrete inflammatory molecules like IL-1 β and IL-18 in a similar manner than microglia, these two cell types might also share the involvement of autophagy in immune-related processes [149, 165]. However, evidence for this hypothesis is lacking. In addition, a function of autophagy in glutamate responses in immortalized rat astrocytes was reported [166]. Glutamate uptake by astrocytes leads to a $Ca²⁺$ release from lysosomes and to autophagy induction. While $Ca²⁺$ elevations trigger gliotransmitter release, autophagy induction could provide metabolic support not only for astrocytes but also for the nearby neurons. Furthermore, parts of the autophagy machinery could play a role in the release of molecules from astrocytes as described for the insulin-degrading enzyme in murine primary astrocytes [167, 168]. This notion is supported by the finding that ATP release to the extracellular space involves autophagic vesicles in HeLa cells, melanoma cells and rat primary astrocytes [169-172] (Figure 3). However, the exact role of autophagy in unconventional secretion in astrocytes remains to be established.

2.3.3. Astrocytic Autophagy in ALS

Although our knowledge about autophagy in astrocytes is very limited, interest in its role in ALS is increasing since the contribution of astrocytes to ALS has been substantiated by several studies. In a mutant SOD1 mouse model it was shown that inclusions appear in astrocytes first and also to a higher extend than in neurons [173]. Remarkably, astrocyte-specific expression of mutant SOD1 did not cause motor neuron degeneration but astrocyte-specific attenuation of mutant SOD1 expression slowed down disease progression in transgenic mice [75, 79]. Moreover, pro-inflammatory conditions as they occur in NDs can induce profound changes in the mitochondrial network of astrocytes. Under these conditions, fragmentation of mitochondria and decreased respiratory capacity was reported. Therefore, functional autophagy is indispensable for astrocytes in an inflammatory environment to maintain the mitochondrial architecture and to prevent an accumulation of ROS [174]. In ALS mice models with mutated FIG4 and VAC14, the majority of p62-containing inclusions were found in astrocytes, highlighting the relevance of autophagic clearance in these cells [61]. Moreover, astrocytes from mice with autophagic-lysosomal dysfunction were shown to contribute directly to neurodegeneration due to an impaired ability to metabolically support neurons as shown for lysosomal storage disorder [175]. Astrocytes seem to assist neurons also in the degradation of their waste. Neurons were reported to extrude protein aggregates and damaged organelles, which were subsequently taken up and degraded by C. elegans astrocytes and astrocytes of the murine optic nerve head[176, 177] (Figure 3). A recent study by Gomez-Arboledas *et al*. further expanded the spectrum of neuronal recycling targets of astrocytes from metabolites (ascorbate) and organelles (mitochondria) to dystrophic neurites, which were shown to be cleared by astrocyte-mediated phagocytosis from injured neurons in murine AD models [158]. The notion that several of the supportive roles of astrocytes seem to involve the autophagy pathway highlights the importance of assessing the impact of ALS-causing mutations in autophagy components on astrocyte function in ALS.

2.4.Oligodendrocytes

2.4.1. General Functions of Oligodendrocytes

Oligodendrocytes are the glial cells of the CNS responsible for axon myelination. Besides electrical insulation of the axon, myelin plays an important function in providing trophic and metabolic supports to axons [178]. Myelinated fibers were already described in 1717 by van Leeuvenhock but at this time the myelin origin was controversial. In the 1920s, Pío del Río-Hortega discovered oligodendrocytes, cells with few processes, and proposed them as myelin producing cells [179]. This theory was not proven until first electron microscopic studies demonstrated a cytoplasmic connection between oligodendrocytes and myelin sheaths [180]. After an initial contact between oligodendrocyte and axon, the oligodendrocyte processes start to extend into myelin sheaths. The leading innermost "tongue" of the myelin sheath wraps around the axon by laying the newly formed myelin layers underneath the existing layer of myelin. Afterwards, all myelin sheaths extend laterally towards the nodes of Ranvier, also known as myelin sheath gaps. After a few wraps of myelin around the axon, compaction starts from the outermost layer extending inwards [181]. Besides securing rapid conduction of action potentials through myelin isolation, oligodendrocytes metabolically support axons. This support is essential, since the compacted myelin limits the metabolic supply from the extracellular space. Within compacted myelin, cytoplasm-rich channels enable the transport of cargo from the oligodendrocyte cell body to the innermost myelin layer facing the axon (adaxonal tongue of myelin) and vice-versa [182]. As a result, oligodendrocytes and myelinated axons are metabolically coupled. Oligodendrocytes are able to import glucose, transform it to lactate or pyruvate and provide it via monocarboxylic acid transporters (MCT1, MCT2) to the axon [183, 184] (Figure 3). This is finely regulated by N-methyl-D-aspartate (NMDA) receptors on oligodendrocytes, which recognize neuronal activity and sequentially mediate the incorporation of additional glucose transporters and thereby increase glucose import [185]. This

metabolic support of axons by oligodendrocytes is reminiscent of the astrocyte-neuron lactate shuttle and essential as depletion of MCT1 in oligodendrocytes led to motor neuron death [184].

2.4.2. Autophagic Roles in Oligodendrocytes

Studies on autophagy in oligodendrocytes are scarce. However, interest in the functional role of autophagy in oligodendrocytes are rising lately. As in most cell types, autophagy can be induced by rapamycin and exerts protein quality control functions in oligodendrocytes. This was shown for example in the rat oligodendroglial cell lines OLN-t40 and OLN-93 [186, 187]. However, under apoptotic conditions rapamycin treatment led to augmented cell death in rat primary oligodendrocytes [188]. In addition, autophagy is involved in myelination, which is one of the main functions of oligodendrocytes. Duncan and colleagues demonstrated that autophagy increases myelination, more specifically myelin thickness and the number of myelinated axons in Long–Evans shaker rats [189]. Furthermore, autophagy was observed to be essential for myelination during development in mice [190]. Clearance of damaged myelin is necessary for maintenance of healthy myelin and normal nerve function. Interestingly, Schwann cells, the counterparts of oligodendrocytes in the peripheral nervous system, are able to degrade myelin after injury by autophagy in a process called myelinophagy. While injury promotes autophagy in Schwann cells in mice, oligodendrocytes appear to be unable to digest myelin, possibly reflecting the poor regenerative capability of the CNS tissue after myelin injury [191]. The conditional deletion of *Atg5* in murine oligodendrocytes by Whittemore and colleagues was instrumental to demonstrate the protective role of autophagy. In this model, the authors observed a reduction of cell viability in response to ER stress [190]. Similarly, in a human oligodendrocyte cell line (MO3.13) with a vanishing white matter disease mutation, autophagy plays a role in ensuring cell survival of oligodendrocytes under ER stress conditions [192]. Given that autophagy is involved in the trophic support of neurons by astrocytes and that oligodendrocytes maintain this function at myelinated axons, it can be assumed that autophagy is also linked to this process in oligodendrocytes. Indeed, Roy *et al.* supported this hypothesis by showing that autophagy promotes the retromer-dependent cell surface trafficking of the nutrient transporters glucose transporter 1 (GLUT1) and MCT1 in mouse embryonic fibroblasts [193] (Figure 3). Therefore, autophagy seems to play an important role in metabolic support of neurons by astrocytes and oligodendrocytes via facilitating increased glucose uptake and increased lactate release.

2.4.3. Oligodendrocytic Autophagy in ALS

While oligodendrocytes and myelin are central to the pathomechanisms of inflammatory diseases such as multiple sclerosis, they are also implicated in the pathology of several NDs. For example, TDP-43 and FUS-positive inclusions were found among other cells in oligodendrocytes in postmortem tissues of ALS patients [194-196]. The occurrence of aggregates in oligodendrocytes in ALS suggests an impairment of autophagy in these cells. Importantly, Rothstein and colleagues observed that MCT1 expression, which is high in oligodendrocytes in otherwise unperturbed conditions, is reduced in in patients with, and mouse models of ALS and correlated with neuronal death in animal and cell culture models [184]. Given that autophagy has been shown to be essential for MCT1 translocation, defective autophagy might at least partially be responsible for the disruption of MCT1 in ALS oligodendrocytes. However, an oligodendrocyte-specific role of autophagy in ALS remains to be formally demonstrated.

Concluding Remarks

Neuroimmune changes and non-cell autonomous toxicity are tightly linked to the pathology of ALS [197]. For example, ALS-related mutant SOD1 expression in microglia and astrocytes was demonstrated to be the decisive source that drives disease progression after onset [115, 198]. Intriguingly, rare mutations in the triggering receptor expressed on myeloid cells 2 (TREM2) gene have recently been linked to increased risk of ALS [199]. Hence, glial modulation emerged as a strategy to slow disease progression in ALS/FTD. Given the crucial role of autophagy and its components in balancing beneficial and detrimental effects of immunity, inflammation and metabolism in other cell types [200], autophagy appears an attractive target for the titration of glial activity to ultimately slow down disease progression. However, despite the progress that has been made in understanding the basic mechanistic principles

underlying autophagy (which has primarily been described in cells culture under extreme conditions of starvation), many unanswered questions remain, in particular with respect to cell type-specific roles of autophagy and autophagy-related pathways as well as with regard to the contribution of defects in these processes to onset and/or progression of NDs. Continuing studies in this area are needed to define and delineate the function of the autophagy machinery in glia cells and its disturbance in ALS/FTD.

Acknowledgements

We thank the members of Behrends laboratory for stimulating discussion. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) within the framework of the Munich Cluster for Systems Neurology (EXC2145 SyNergy), the Collaborative Research Center (CRC1177) and the project grant BE 4685/2-1 as well as by the Boehringer Ingelheim Foundation.

Figure legend

Figure 1. The autophagic pathway. The ULK protein and the PI3K-III lipid kinase complex control the formation of phagophores. Cargo is recruited to these phagophores by ATG8 family proteins and autophagic receptors. Subsequent membrane elongation results in closed, mature autophagosomes. These autophagosomes undergoes several fusion events with late endosomal compartments and lysosomes. In these autolysosomes, cargo is broken down by lysosomal hydrolases.

Figure 2. ALS genes and their possible involvement in the autophagic pathway. A large number of ALS genes (indicated in green) have direct or indirect functions in the autophagy pathway including roles as autophagic receptors (dark green). In addition, some mutated forms of ALS-associated proteins interfere with autophagy (red).

Figure 3. Degradative and non-degradative roles of the autophagic machinery in glial cells. (a) Degradation of endogenous and exogenous toxic proteins and organelles. (b) Unconventional secretion. (c) Regulation of the inflammasome. (d) Trafficking of the nutrient transporters glucose transporter 1 (GLUT1) and monocarboxylic acid transporter 1 (MCT1). (e) Transport of cytosolic antigens into the lumen of major histocompatibility complex (MHC)-II compartment. (f) Regulation of the secretion of soluble factors, which influence synaptic pruning. Not all functions take exclusively place in the indicated cell type.

References

[1] J.S. King, Autophagy across the eukaryotes: is S. cerevisiae the odd one out?, Autophagy 8(7) (2012) 1159-62.

[2] C. de Duve, Lysosomes revisited, Eur J Biochem 137(3) (1983) 391-7.

[3] S. Kaushik, A.M. Cuervo, Chaperone-mediated autophagy: a unique way to enter the lysosome world, Trends Cell Biol 22(8) (2012) 407-17.

[4] L. Marzella, J. Ahlberg, H. Glaumann, Autophagy, heterophagy, microautophagy and crinophagy as the means for intracellular degradation, Virchows Arch B Cell Pathol Incl Mol Pathol 36(2-3) (1981) 219-34.

[5] G. Kroemer, G. Marino, B. Levine, Autophagy and the integrated stress response, Mol Cell 40(2) (2010) 280-93.

[6] Y. Fujioka, S.W. Suzuki, H. Yamamoto, C. Kondo-Kakuta, Y. Kimura, H. Hirano, R. Akada, F. Inagaki, Y. Ohsumi, N.N. Noda, Structural basis of starvation-induced assembly of the autophagy initiation complex, Nat Struct Mol Biol 21(6) (2014) 513-21.

[7] J. Kim, M. Kundu, B. Viollet, K.L. Guan, AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1, Nat Cell Biol 13(2) (2011) 132-41.

[8] N. Hosokawa, T. Sasaki, S. Iemura, T. Natsume, T. Hara, N. Mizushima, Atg101, a novel mammalian autophagy protein interacting with Atg13, Autophagy 5(7) (2009) 973-9.

[9] F.M. Menzies, A. Fleming, A. Caricasole, C.F. Bento, S.P. Andrews, A. Ashkenazi, J. Fullgrabe, A. Jackson, M. Jimenez Sanchez, C. Karabiyik, F. Licitra, A. Lopez Ramirez, M. Pavel, C. Puri, M. Renna, T. Ricketts, L. Schlotawa, M. Vicinanza, H. Won, Y. Zhu, J. Skidmore, D.C. Rubinsztein, Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities, Neuron 93(5) (2017) 1015-1034.

[10] E.L. Axe, S.A. Walker, M. Manifava, P. Chandra, H.L. Roderick, A. Habermann, G. Griffiths, N.T. Ktistakis, Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3 phosphate and dynamically connected to the endoplasmic reticulum, J Cell Biol 182(4) (2008) 685- 701.

[11] H.E. Polson, J. de Lartigue, D.J. Rigden, M. Reedijk, S. Urbe, M.J. Clague, S.A. Tooze, Mammalian Atg18 (WIPI2) localizes to omegasome-anchored phagophores and positively regulates LC3 lipidation, Autophagy 6(4) (2010) 506-22.

[12] J. Geng, U. Nair, K. Yasumura-Yorimitsu, D.J. Klionsky, Post-Golgi Sec proteins are required for autophagy in Saccharomyces cerevisiae, Mol Biol Cell 21(13) (2010) 2257-69.

[13] D.W. Hailey, A.S. Rambold, P. Satpute-Krishnan, K. Mitra, R. Sougrat, P.K. Kim, J. Lippincott-Schwartz, Mitochondria supply membranes for autophagosome biogenesis during starvation, Cell 141(4) (2010) 656-67.

[14] B. Ravikumar, K. Moreau, L. Jahreiss, C. Puri, D.C. Rubinsztein, Plasma membrane contributes to the formation of pre-autophagosomal structures, Nat Cell Biol 12(8) (2010) 747-57.

[15] H.C. Dooley, M. Razi, H.E. Polson, S.E. Girardin, M.I. Wilson, S.A. Tooze, WIPI2 links LC3 conjugation with PI3P, autophagosome formation, and pathogen clearance by recruiting Atg12-5- 16L1, Mol Cell 55(2) (2014) 238-52.

[16] M. Sakoh-Nakatogawa, K. Matoba, E. Asai, H. Kirisako, J. Ishii, N.N. Noda, F. Inagaki, H. Nakatogawa, Y. Ohsumi, Atg12-Atg5 conjugate enhances E2 activity of Atg3 by rearranging its catalytic site, Nat Struct Mol Biol 20(4) (2013) 433-9.

[17] M.R. Slobodkin, Z. Elazar, The Atg8 family: multifunctional ubiquitin-like key regulators of autophagy, Essays Biochem 55 (2013) 51-64.

[18] H. Weidberg, E. Shvets, T. Shpilka, F. Shimron, V. Shinder, Z. Elazar, LC3 and GATE-16/GABARAP subfamilies are both essential yet act differently in autophagosome biogenesis, EMBO J 29(11) (2010) 1792-802.

[19] R.L. Knorr, R. Lipowsky, R. Dimova, Autophagosome closure requires membrane scission, Autophagy 11(11) (2015) 2134-2137.

[20] B.P. Lawrence, W.J. Brown, Autophagic vacuoles rapidly fuse with pre-existing lysosomes in cultured hepatocytes, J Cell Sci 102 (Pt 3) (1992) 515-26.

[21] L. Jahreiss, F.M. Menzies, D.C. Rubinsztein, The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes, Traffic 9(4) (2008) 574-87.

[22] S. Kimura, T. Noda, T. Yoshimori, Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3, Autophagy 3(5) (2007) 452-60.

[23] T.P. Ashford, K.R. Porter, Cytoplasmic components in hepatic cell lysosomes, J Cell Biol 12 (1962) 198-202.

[24] C. De Duve, R. Wattiaux, Functions of lysosomes, Annu Rev Physiol 28 (1966) 435-92.

[25] G.E. Mortimore, C.M. Schworer, Induction of autophagy by amino-acid deprivation in perfused rat liver, Nature 270(5633) (1977) 174-6.

[26] C. Canto, J. Auwerx, Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?, Pharmacol Rev 64(1) (2012) 166-87.

[27] D.G. Hardie, F.A. Ross, S.A. Hawley, AMPK: a nutrient and energy sensor that maintains energy homeostasis, Nat Rev Mol Cell Biol 13(4) (2012) 251-62.

[28] A. Stolz, A. Ernst, I. Dikic, Cargo recognition and trafficking in selective autophagy, Nat Cell Biol 16(6) (2014) 495-501.

[29] A. Khaminets, C. Behl, I. Dikic, Ubiquitin-Dependent And Independent Signals In Selective Autophagy, Trends Cell Biol 26(1) (2016) 6-16.

[30] C. Behrends, S. Fulda, Receptor proteins in selective autophagy, Int J Cell Biol 2012 (2012) 673290.

[31] P. Grumati, I. Dikic, Ubiquitin signaling and autophagy, J Biol Chem 293(15) (2018) 5404-5413. [32] N.N. Noda, H. Kumeta, H. Nakatogawa, K. Satoo, W. Adachi, J. Ishii, Y. Fujioka, Y. Ohsumi, F. Inagaki, Structural basis of target recognition by Atg8/LC3 during selective autophagy, Genes Cells 13(12) (2008) 1211-8.

[33] V. Rogov, V. Dotsch, T. Johansen, V. Kirkin, Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy, Mol Cell 53(2) (2014) 167-78. [34] S. Subramani, V. Malhotra, Non-autophagic roles of autophagy-related proteins, EMBO Rep 14(2) (2013) 143-51.

[35] J.M. Duran, C. Anjard, C. Stefan, W.F. Loomis, V. Malhotra, Unconventional secretion of Acb1 is mediated by autophagosomes, J Cell Biol 188(4) (2010) 527-36.

[36] M. Zhang, R. Schekman, Cell biology. Unconventional secretion, unconventional solutions, Science 340(6132) (2013) 559-61.

[37] C. Rabouille, Pathways of Unconventional Protein Secretion, Trends Cell Biol 27(3) (2017) 230- 240.

[38] M.M. Young, Y. Takahashi, O. Khan, S. Park, T. Hori, J. Yun, A.K. Sharma, S. Amin, C.D. Hu, J. Zhang, M. Kester, H.G. Wang, Autophagosomal membrane serves as platform for intracellular deathinducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis, J Biol Chem 287(15) (2012) 12455-68.

[39] S. Bialik, S.K. Dasari, A. Kimchi, Autophagy-dependent cell death - where, how and why a cell eats itself to death, J Cell Sci 131(18) (2018).

[40] P.R. Talbot, P.J. Goulding, J.J. Lloyd, J.S. Snowden, D. Neary, H.J. Testa, Inter-relation between "classic" motor neuron disease and frontotemporal dementia: neuropsychological and single photon emission computed tomography study, J Neurol Neurosurg Psychiatry 58(5) (1995) 541-7. [41] J.R. Burrell, G.M. Halliday, J.J. Kril, L.M. Ittner, J. Gotz, M.C. Kiernan, J.R. Hodges, The frontotemporal dementia-motor neuron disease continuum, Lancet 388(10047) (2016) 919-31. [42] M. Neumann, D.M. Sampathu, L.K. Kwong, A.C. Truax, M.C. Micsenyi, T.T. Chou, J. Bruce, T. Schuck, M. Grossman, C.M. Clark, L.F. McCluskey, B.L. Miller, E. Masliah, I.R. Mackenzie, H. Feldman, W. Feiden, H.A. Kretzschmar, J.Q. Trojanowski, V.M. Lee, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science 314(5796) (2006) 130-3. [43] E. Kabashi, P.N. Valdmanis, P. Dion, D. Spiegelman, B.J. McConkey, C. Vande Velde, J.P. Bouchard, L. Lacomblez, K. Pochigaeva, F. Salachas, P.F. Pradat, W. Camu, V. Meininger, N. Dupre, G.A. Rouleau, TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis, Nat Genet 40(5) (2008) 572-4.

[44] J. Sreedharan, I.P. Blair, V.B. Tripathi, X. Hu, C. Vance, B. Rogelj, S. Ackerley, J.C. Durnall, K.L. Williams, E. Buratti, F. Baralle, J. de Belleroche, J.D. Mitchell, P.N. Leigh, A. Al-Chalabi, C.C. Miller, G. Nicholson, C.E. Shaw, TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis, Science 319(5870) (2008) 1668-72.

[45] S.L. Rea, J.P. Walsh, R. Layfield, T. Ratajczak, J. Xu, New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget's disease of bone, Endocr Rev 34(4) (2013) 501- 24.

[46] Y.C. Wong, E.L. Holzbaur, Optineurin is an autophagy receptor for damaged mitochondria in parkin-mediated mitophagy that is disrupted by an ALS-linked mutation, Proc Natl Acad Sci U S A 111(42) (2014) E4439-48.

[47] C. Rothenberg, D. Srinivasan, L. Mah, S. Kaushik, C.M. Peterhoff, J. Ugolino, S. Fang, A.M. Cuervo, R.A. Nixon, M.J. Monteiro, Ubiquilin functions in autophagy and is degraded by chaperonemediated autophagy, Hum Mol Genet 19(16) (2010) 3219-32.

[48] E.T. Cirulli, B.N. Lasseigne, S. Petrovski, P.C. Sapp, P.A. Dion, C.S. Leblond, J. Couthouis, Y.F. Lu, Q. Wang, B.J. Krueger, Z. Ren, J. Keebler, Y. Han, S.E. Levy, B.E. Boone, J.R. Wimbish, L.L. Waite, A.L. Jones, J.P. Carulli, A.G. Day-Williams, J.F. Staropoli, W.W. Xin, A. Chesi, A.R. Raphael, D. McKenna-Yasek, J. Cady, J.M. Vianney de Jong, K.P. Kenna, B.N. Smith, S. Topp, J. Miller, A. Gkazi, F.S. Consortium, A. Al-Chalabi, L.H. van den Berg, J. Veldink, V. Silani, N. Ticozzi, C.E. Shaw, R.H. Baloh, S. Appel, E. Simpson, C. Lagier-Tourenne, S.M. Pulst, S. Gibson, J.Q. Trojanowski, L. Elman, L. McCluskey, M. Grossman, N.A. Shneider, W.K. Chung, J.M. Ravits, J.D. Glass, K.B. Sims, V.M. Van Deerlin, T. Maniatis, S.D. Hayes, A. Ordureau, S. Swarup, J. Landers, F. Baas, A.S. Allen, R.S. Bedlack, J.W. Harper, A.D. Gitler, G.A. Rouleau, R. Brown, M.B. Harms, G.M. Cooper, T. Harris, R.M. Myers, D.B. Goldstein, Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways, Science 347(6229) (2015) 1436-41.

[49] C. Sellier, M.L. Campanari, C. Julie Corbier, A. Gaucherot, I. Kolb-Cheynel, M. Oulad-Abdelghani, F. Ruffenach, A. Page, S. Ciura, E. Kabashi, N. Charlet-Berguerand, Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death, EMBO J 35(12) (2016) 1276-97.

[50] P.M. Sullivan, X. Zhou, A.M. Robins, D.H. Paushter, D. Kim, M.B. Smolka, F. Hu, The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway, Acta Neuropathol Commun 4(1) (2016) 51.

[51] Y. Shi, S. Lin, K.A. Staats, Y. Li, W.H. Chang, S.T. Hung, E. Hendricks, G.R. Linares, Y. Wang, E.Y. Son, X. Wen, K. Kisler, B. Wilkinson, L. Menendez, T. Sugawara, P. Woolwine, M. Huang, M.J. Cowan, B. Ge, N. Koutsodendris, K.P. Sandor, J. Komberg, V.R. Vangoor, K. Senthilkumar, V. Hennes, C. Seah, A.R. Nelson, T.Y. Cheng, S.J. Lee, P.R. August, J.A. Chen, N. Wisniewski, V. Hanson-Smith, T.G. Belgard, A. Zhang, M. Coba, C. Grunseich, M.E. Ward, L.H. van den Berg, R.J.

Pasterkamp, D. Trotti, B.V. Zlokovic, J.K. Ichida, Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons, Nat Med 24(3) (2018) 313-325.

[52] D. Wu, Z. Hao, H. Ren, G. Wang, Loss of VAPB Regulates Autophagy in a Beclin 1-Dependent Manner, Neurosci Bull 34(6) (2018) 1037-1046.

[53] K.Y. Soo, J. Sultana, A.E. King, R. Atkinson, S.T. Warraich, V. Sundaramoorthy, I. Blair, M.A. Farg, J.D. Atkin, ALS-associated mutant FUS inhibits macroautophagy which is restored by overexpression of Rab1, Cell Death Discov 1 (2015) 15030.

[54] B. Ravikumar, S. Imarisio, S. Sarkar, C.J. O'Kane, D.C. Rubinsztein, Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease, J Cell Sci 121(Pt 10) (2008) 1649-60.

[55] Z. Szatmari, M. Sass, The autophagic roles of Rab small GTPases and their upstream regulators: a review, Autophagy 10(7) (2014) 1154-66.

[56] A. Lee, S.L. Rayner, S.S.L. Gwee, A. De Luca, H. Shahheydari, V. Sundaramoorthy, A. Ragagnin, M. Morsch, R. Radford, J. Galper, S. Freckleton, B. Shi, A.K. Walker, E.K. Don, N.J. Cole, S. Yang, K.L. Williams, J.J. Yerbury, I.P. Blair, J.D. Atkin, M.P. Molloy, R.S. Chung, Pathogenic mutation in the ALS/FTD gene, CCNF, causes elevated Lys48-linked ubiquitylation and defective autophagy, Cell Mol Life Sci 75(2) (2018) 335-354.

[57] J.K. Bose, C.C. Huang, C.K. Shen, Regulation of autophagy by neuropathological protein TDP-43, J Biol Chem 286(52) (2011) 44441-8.

[58] E. Tresse, F.A. Salomons, J. Vesa, L.C. Bott, V. Kimonis, T.P. Yao, N.P. Dantuma, J.P. Taylor, VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD, Autophagy 6(2) (2010) 217-27.

[59] M. Filimonenko, S. Stuffers, C. Raiborg, A. Yamamoto, L. Malerod, E.M. Fisher, A. Isaacs, A. Brech, H. Stenmark, A. Simonsen, Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease, J Cell Biol 179(3) (2007) 485-500.

[60] H. Urwin, A. Authier, J.E. Nielsen, D. Metcalf, C. Powell, K. Froud, D.S. Malcolm, I. Holm, P. Johannsen, J. Brown, E.M. Fisher, J. van der Zee, M. Bruyland, F.R. Consortium, C. Van Broeckhoven, J. Collinge, S. Brandner, C. Futter, A.M. Isaacs, Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations, Hum Mol Genet 19(11) (2010) 2228-38.

[61] C.J. Ferguson, G.M. Lenk, M.H. Meisler, Defective autophagy in neurons and astrocytes from mice deficient in PI(3,5)P2, Hum Mol Genet 18(24) (2009) 4868-78.

[62] I. Vaccari, A. Carbone, S.C. Previtali, Y.A. Mironova, V. Alberizzi, R. Noseda, C. Rivellini, F. Bianchi, U. Del Carro, M. D'Antonio, G.M. Lenk, L. Wrabetz, R.J. Giger, M.H. Meisler, A. Bolino, Loss of Fig4 in both Schwann cells and motor neurons contributes to CMT4J neuropathy, Hum Mol Genet 24(2) (2015) 383-96.

[63] A. Otomo, R. Kunita, K. Suzuki-Utsunomiya, J.E. Ikeda, S. Hadano, Defective relocalization of ALS2/alsin missense mutants to Rac1-induced macropinosomes accounts for loss of their cellular function and leads to disturbed amphisome formation, FEBS Lett 585(5) (2011) 730-6.

[64] J.S. Ju, R.A. Fuentealba, S.E. Miller, E. Jackson, D. Piwnica-Worms, R.H. Baloh, C.C. Weihl, Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease, J Cell Biol 187(6) (2009) 875-88.

[65] K. Ikenaka, K. Kawai, M. Katsuno, Z. Huang, Y.M. Jiang, Y. Iguchi, K. Kobayashi, T. Kimata, M. Waza, F. Tanaka, I. Mori, G. Sobue, dnc-1/dynactin 1 knockdown disrupts transport of

autophagosomes and induces motor neuron degeneration, PLoS One 8(2) (2013) e54511. [66] J. Chang, S. Lee, C. Blackstone, Spastic paraplegia proteins spastizin and spatacsin mediate autophagic lysosome reformation, J Clin Invest 124(12) (2014) 5249-62.

[67] M. Nassif, V. Valenzuela, D. Rojas-Rivera, R. Vidal, S. Matus, K. Castillo, Y. Fuentealba, G. Kroemer, B. Levine, C. Hetz, Pathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis, Autophagy 10(7) (2014) 1256-71.

[68] Y. Xie, B. Zhou, M.Y. Lin, S. Wang, K.D. Foust, Z.H. Sheng, Endolysosomal Deficits Augment Mitochondria Pathology in Spinal Motor Neurons of Asymptomatic fALS Mice, Neuron 87(2) (2015) 355-70.

[69] A. Al-Chalabi, L.H. van den Berg, J. Veldink, Gene discovery in amyotrophic lateral sclerosis: implications for clinical management, Nat Rev Neurol 13(2) (2017) 96-104.

[70] T. Zu, B. Gibbens, N.S. Doty, M. Gomes-Pereira, A. Huguet, M.D. Stone, J. Margolis, M. Peterson, T.W. Markowski, M.A. Ingram, Z. Nan, C. Forster, W.C. Low, B. Schoser, N.V. Somia, H.B. Clark, S. Schmechel, P.B. Bitterman, G. Gourdon, M.S. Swanson, M. Moseley, L.P. Ranum, Non-ATG-initiated translation directed by microsatellite expansions, Proc Natl Acad Sci U S A 108(1) (2011) 260-5.

[71] S. Mizielinska, T. Lashley, F.E. Norona, E.L. Clayton, C.E. Ridler, P. Fratta, A.M. Isaacs, C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci, Acta Neuropathol 126(6) (2013) 845-57.

[72] K. Forsberg, P.M. Andersen, S.L. Marklund, T. Brannstrom, Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis, Acta Neuropathol 121(5) (2011) 623-34.

[73] D.W. Miller, M.R. Cookson, D.W. Dickson, Glial cell inclusions and the pathogenesis of neurodegenerative diseases, Neuron Glia Biol 1(1) (2004) 13-21.

[74] S. Boillee, C. Vande Velde, D.W. Cleveland, ALS: a disease of motor neurons and their nonneuronal neighbors, Neuron 52(1) (2006) 39-59.

[75] Y.H. Gong, A.S. Parsadanian, A. Andreeva, W.D. Snider, J.L. Elliott, Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration, J Neurosci 20(2) (2000) 660-5.

[76] M.M. Lino, C. Schneider, P. Caroni, Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease, J Neurosci 22(12) (2002) 4825-32. [77] M. Madill, K. McDonagh, J. Ma, A. Vajda, P. McLoughlin, T. O'Brien, O. Hardiman, S. Shen, Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms, Mol Brain 10(1) (2017) 22.

[78] F. Massenzio, E. Pena-Altamira, S. Petralla, M. Virgili, G. Zuccheri, A. Miti, E. Polazzi, I. Mengoni, D. Piffaretti, B. Monti, Microglial overexpression of fALS-linked mutant SOD1 induces SOD1 processing impairment, activation and neurotoxicity and is counteracted by the autophagy inducer trehalose, Biochim Biophys Acta Mol Basis Dis 1864(12) (2018) 3771-3785.

[79] K. Yamanaka, S.J. Chun, S. Boillee, N. Fujimori-Tonou, H. Yamashita, D.H. Gutmann, R. Takahashi, H. Misawa, D.W. Cleveland, Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis, Nat Neurosci 11(3) (2008) 251-3.

[80] L.J. Lawson, V.H. Perry, P. Dri, S. Gordon, Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain, Neuroscience 39(1) (1990) 151-70.

[81] F. Ginhoux, S. Lim, G. Hoeffel, D. Low, T. Huber, Origin and differentiation of microglia, Front Cell Neurosci 7 (2013) 45.

[82] F. Ginhoux, S. Garel, The mysterious origins of microglia, Nat Neurosci 21(7) (2018) 897-899. [83] R. Hanamsagar, S.D. Bilbo, Environment matters: microglia function and dysfunction in a changing world, Curr Opin Neurobiol 47 (2017) 146-155.

[84] A. Nimmerjahn, F. Kirchhoff, F. Helmchen, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science 308(5726) (2005) 1314-8.

[85] T. Kielian, Toll-like receptors in central nervous system glial inflammation and homeostasis, J Neurosci Res 83(5) (2006) 711-30.

[86] J.M. Pocock, H. Kettenmann, Neurotransmitter receptors on microglia, Trends Neurosci 30(10) (2007) 527-35.

[87] M. Lv, Y. Liu, J. Zhang, L. Sun, Z. Liu, S. Zhang, B. Wang, D. Su, Z. Su, Roles of inflammation response in microglia cell through Toll-like receptors 2/interleukin-23/interleukin-17 pathway in cerebral ischemia/reperfusion injury, Neuroscience 176 (2011) 162-72.

[88] K. Saijo, A. Crotti, C.K. Glass, Regulation of microglia activation and deactivation by nuclear receptors, Glia 61(1) (2013) 104-11.

[89] H. Keren-Shaul, A. Spinrad, A. Weiner, O. Matcovitch-Natan, R. Dvir-Szternfeld, T.K. Ulland, E. David, K. Baruch, D. Lara-Astaiso, B. Toth, S. Itzkovitz, M. Colonna, M. Schwartz, I. Amit, A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease, Cell 169(7) (2017) 1276-1290 e17.

[90] R.M. Ransohoff, A polarizing question: do M1 and M2 microglia exist?, Nat Neurosci 19(8) (2016) 987-91.

[91] C. Sousa, K. Biber, A. Michelucci, Cellular and Molecular Characterization of Microglia: A Unique Immune Cell Population, Front Immunol 8 (2017) 198.

[92] I. Nakagawa, A. Amano, N. Mizushima, A. Yamamoto, H. Yamaguchi, T. Kamimoto, A. Nara, J. Funao, M. Nakata, K. Tsuda, S. Hamada, T. Yoshimori, Autophagy defends cells against invading group A Streptococcus, Science 306(5698) (2004) 1037-40.

[93] M.G. Gutierrez, S.S. Master, S.B. Singh, G.A. Taylor, M.I. Colombo, V. Deretic, Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages, Cell 119(6) (2004) 753-66.

[94] C.S. Shi, J.H. Kehrl, TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy, Sci Signal 3(123) (2010) ra42.

[95] M.A. Delgado, R.A. Elmaoued, A.S. Davis, G. Kyei, V. Deretic, Toll-like receptors control autophagy, EMBO J 27(7) (2008) 1110-21.

[96] D. Zhou, P. Li, Y. Lin, J.M. Lott, A.D. Hislop, D.H. Canaday, R.R. Brutkiewicz, J.S. Blum, Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens, Immunity 22(5) (2005) 571-81.

[97] H.K. Lee, L.M. Mattei, B.E. Steinberg, P. Alberts, Y.H. Lee, A. Chervonsky, N. Mizushima, S. Grinstein, A. Iwasaki, In vivo requirement for Atg5 in antigen presentation by dendritic cells, Immunity 32(2) (2010) 227-39.

[98] T. Saitoh, N. Fujita, M.H. Jang, S. Uematsu, B.G. Yang, T. Satoh, H. Omori, T. Noda, N. Yamamoto, M. Komatsu, K. Tanaka, T. Kawai, T. Tsujimura, O. Takeuchi, T. Yoshimori, S. Akira, Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production, Nature 456(7219) (2008) 264-8.

[99] K. Nakahira, J.A. Haspel, V.A. Rathinam, S.J. Lee, T. Dolinay, H.C. Lam, J.A. Englert, M. Rabinovitch, M. Cernadas, H.P. Kim, K.A. Fitzgerald, S.W. Ryter, A.M. Choi, Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome, Nat Immunol 12(3) (2011) 222-30.

[100] R. Zhou, A.S. Yazdi, P. Menu, J. Tschopp, A role for mitochondria in NLRP3 inflammasome activation, Nature 469(7329) (2011) 221-5.

[101] Q. Liu, D. Zhang, D. Hu, X. Zhou, Y. Zhou, The role of mitochondria in NLRP3 inflammasome activation, Mol Immunol 103 (2018) 115-124.

[102] N. Dupont, S. Jiang, M. Pilli, W. Ornatowski, D. Bhattacharya, V. Deretic, Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta, EMBO J 30(23) (2011) 4701- 11.

[103] L.J. Wang, H.Y. Huang, M.P. Huang, W. Liou, Y.T. Chang, C.C. Wu, D.M. Ojcius, Y.S. Chang, The microtubule-associated protein EB1 links AIM2 inflammasomes with autophagy-dependent secretion, J Biol Chem 289(42) (2014) 29322-33.

[104] C.L. Evavold, J. Ruan, Y. Tan, S. Xia, H. Wu, J.C. Kagan, The Pore-Forming Protein Gasdermin D Regulates Interleukin-1 Secretion from Living Macrophages, Immunity 48(1) (2018) 35-44 e6. [105] L. Sborgi, S. Ruhl, E. Mulvihill, J. Pipercevic, R. Heilig, H. Stahlberg, C.J. Farady, D.J. Muller, P. Broz, S. Hiller, GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death, EMBO J 35(16) (2016) 1766-78.

[106] J. Harris, M. Hartman, C. Roche, S.G. Zeng, A. O'Shea, F.A. Sharp, E.M. Lambe, E.M. Creagh, D.T. Golenbock, J. Tschopp, H. Kornfeld, K.A. Fitzgerald, E.C. Lavelle, Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation, J Biol Chem 286(11) (2011) 9587-97.

[107] J.S. Ainscough, G. Frank Gerberick, M. Zahedi-Nejad, G. Lopez-Castejon, D. Brough, I. Kimber, R.J. Dearman, Dendritic cell IL-1alpha and IL-1beta are polyubiquitinated and degraded by the proteasome, J Biol Chem 289(51) (2014) 35582-92.

[108] M.J.G. Eldridge, J. Sanchez-Garrido, G.F. Hoben, P.J. Goddard, A.R. Shenoy, The Atypical Ubiquitin E2 Conjugase UBE2L3 Is an Indirect Caspase-1 Target and Controls IL-1beta Secretion by Inflammasomes, Cell Rep 18(5) (2017) 1285-1297.

[109] F. Martinon, K. Burns, J. Tschopp, The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta, Mol Cell 10(2) (2002) 417-26.

[110] Q. Sun, J. Fan, T.R. Billiar, M.J. Scott, Inflammasome and autophagy regulation - a two-way street, Mol Med 23 (2017) 188-195.

[111] G. Morello, A.G. Spampinato, S. Cavallaro, Neuroinflammation and ALS: Transcriptomic Insights into Molecular Disease Mechanisms and Therapeutic Targets, Mediators Inflamm 2017 (2017) 7070469.

[112] T. Kawamata, H. Akiyama, T. Yamada, P.L. McGeer, Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue, Am J Pathol 140(3) (1992) 691-707.

[113] M.E. Alexianu, M. Kozovska, S.H. Appel, Immune reactivity in a mouse model of familial ALS correlates with disease progression, Neurology 57(7) (2001) 1282-9.

[114] J. Brettschneider, J.B. Toledo, V.M. Van Deerlin, L. Elman, L. McCluskey, V.M. Lee, J.Q. Trojanowski, Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis, PLoS One 7(6) (2012) e39216.

[115] D.R. Beers, J.S. Henkel, Q. Xiao, W. Zhao, J. Wang, A.A. Yen, L. Siklos, S.R. McKercher, S.H. Appel, Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis, Proc Natl Acad Sci U S A 103(43) (2006) 16021-6.

[116] M. Poloni, D. Facchetti, R. Mai, A. Micheli, L. Agnoletti, G. Francolini, G. Mora, C. Camana, L. Mazzini, T. Bachetti, Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis, Neurosci Lett 287(3) (2000) 211- 4.

[117] C. Cereda, C. Baiocchi, P. Bongioanni, E. Cova, S. Guareschi, M.R. Metelli, B. Rossi, I. Sbalsi, M.C. Cuccia, M. Ceroni, TNF and sTNFR1/2 plasma levels in ALS patients, J Neuroimmunol 194(1-2) (2008) 123-31.

[118] M.K. McCoy, M.G. Tansey, TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease, J Neuroinflammation 5 (2008) 45.

[119] M.-m. Jin, F. Wang, D. Qi, W.-w. Liu, C. Gu, C.-J. Mao, Y.-P. Yang, Z. Zhao, L.-F. Hu, C.-F. Liu, A Critical Role of Autophagy in Regulating Microglia Polarization in Neurodegeneration, Frontiers in Aging Neuroscience 10(378) (2018).

[120] C. Bussi, J.M. Peralta Ramos, D.S. Arroyo, E.A. Gaviglio, J.I. Gallea, J.M. Wang, M.S. Celej, P. Iribarren, Autophagy down regulates pro-inflammatory mediators in BV2 microglial cells and rescues both LPS and alpha-synuclein induced neuronal cell death, Sci Rep 7 (2017) 43153.

[121] H.J. Kim, M.H. Cho, W.H. Shim, J.K. Kim, E.Y. Jeon, D.H. Kim, S.Y. Yoon, Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects, Mol Psychiatry 22(11) (2017) 1576-1584.

[122] J.G. O'Rourke, L. Bogdanik, A. Yanez, D. Lall, A.J. Wolf, A.K. Muhammad, R. Ho, S. Carmona, J.P. Vit, J. Zarrow, K.J. Kim, S. Bell, M.B. Harms, T.M. Miller, C.A. Dangler, D.M. Underhill, H.S. Goodridge, C.M. Lutz, R.H. Baloh, C9orf72 is required for proper macrophage and microglial function in mice, Science 351(6279) (2016) 1324-9.

[123] J. Chew, T.F. Gendron, M. Prudencio, H. Sasaguri, Y.J. Zhang, M. Castanedes-Casey, C.W. Lee, K. Jansen-West, A. Kurti, M.E. Murray, K.F. Bieniek, P.O. Bauer, E.C. Whitelaw, L. Rousseau, J.N. Stankowski, C. Stetler, L.M. Daughrity, E.A. Perkerson, P. Desaro, A. Johnston, K. Overstreet, D. Edbauer, R. Rademakers, K.B. Boylan, D.W. Dickson, J.D. Fryer, L. Petrucelli, Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits, Science 348(6239) (2015) 1151-4.

[124] Y. Liu, A. Pattamatta, T. Zu, T. Reid, O. Bardhi, D.R. Borchelt, A.T. Yachnis, L.P. Ranum, C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD, Neuron 90(3) (2016) 521-34.

[125] B.T. Selvaraj, M.R. Livesey, C. Zhao, J.M. Gregory, O.T. James, E.M. Cleary, A.K. Chouhan, A.B. Gane, E.M. Perkins, O. Dando, S.G. Lillico, Y.B. Lee, A.L. Nishimura, U. Poreci, S. Thankamony, M. Pray, N.A. Vasistha, D. Magnani, S. Borooah, K. Burr, D. Story, A. McCampbell, C.E. Shaw, P.C. Kind, T.J. Aitman, C.B.A. Whitelaw, I. Wilmut, C. Smith, G.B. Miles, G.E. Hardingham, D.J.A. Wyllie, S. Chandran, C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca(2+)-permeable AMPA receptor-mediated excitotoxicity, Nat Commun 9(1) (2018) 347.

[126] S. Ciura, C. Sellier, M.L. Campanari, N. Charlet-Berguerand, E. Kabashi, The most prevalent genetic cause of ALS-FTD, C9orf72 synergizes the toxicity of ATXN2 intermediate polyglutamine repeats through the autophagy pathway, Autophagy 12(8) (2016) 1406-8.

[127] J. Jung, A. Nayak, V. Schaeffer, T. Starzetz, A.K. Kirsch, S. Muller, I. Dikic, M. Mittelbronn, C. Behrends, Multiplex image-based autophagy RNAi screening identifies SMCR8 as ULK1 kinase activity and gene expression regulator, Elife 6 (2017).

[128] E.A. Bushong, M.E. Martone, Y.Z. Jones, M.H. Ellisman, Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains, J Neurosci 22(1) (2002) 183-92.

[129] M.M. Halassa, T. Fellin, H. Takano, J.H. Dong, P.G. Haydon, Synaptic islands defined by the territory of a single astrocyte, J Neurosci 27(24) (2007) 6473-7.

[130] A. Peters, S.L. Palay, H.d. Webster, The fine structure of the nervous system : neurons and their supporting cells, Oxford University Press, New York, 1991.

[131] B.A. MacVicar, E.A. Newman, Astrocyte regulation of blood flow in the brain, Cold Spring Harb Perspect Biol 7(5) (2015).

[132] W.S. Chung, N.J. Allen, C. Eroglu, Astrocytes Control Synapse Formation, Function, and Elimination, Cold Spring Harb Perspect Biol 7(9) (2015) a020370.

[133] I. Allaman, M. Belanger, P.J. Magistretti, Astrocyte-neuron metabolic relationships: for better and for worse, Trends Neurosci 34(2) (2011) 76-87.

[134] N.B. Hamilton, D. Attwell, Do astrocytes really exocytose neurotransmitters?, Nat Rev Neurosci 11(4) (2010) 227-38.

[135] P.J. Magistretti, Neuron-glia metabolic coupling and plasticity, J Exp Biol 209(Pt 12) (2006) 2304-11.

[136] M. Tsacopoulos, P.J. Magistretti, Metabolic coupling between glia and neurons, J Neurosci 16(3) (1996) 877-85.

[137] A.M. Brown, S. Baltan Tekkok, B.R. Ransom, Energy transfer from astrocytes to axons: the role of CNS glycogen, Neurochem Int 45(4) (2004) 529-36.

[138] A.M. Brown, B.R. Ransom, Astrocyte glycogen and brain energy metabolism, Glia 55(12) (2007) 1263-71.

[139] G. Dallerac, O. Chever, N. Rouach, How do astrocytes shape synaptic transmission? Insights from electrophysiology, Front Cell Neurosci 7 (2013) 159.

[140] L.P. Savtchenko, L. Bard, T.P. Jensen, J.P. Reynolds, I. Kraev, N. Medvedev, M.G. Stewart, C. Henneberger, D.A. Rusakov, Disentangling astroglial physiology with a realistic cell model in silico, Nat Commun 9(1) (2018) 3554.

[141] M. Navarrete, G. Perea, L. Maglio, J. Pastor, R. Garcia de Sola, A. Araque, Astrocyte calcium signal and gliotransmission in human brain tissue, Cereb Cortex 23(5) (2013) 1240-6.

[142] C. Murphy-Royal, J. Dupuis, L. Groc, S.H.R. Oliet, Astroglial glutamate transporters in the brain: Regulating neurotransmitter homeostasis and synaptic transmission, J Neurosci Res 95(11) (2017) 2140-2151.

[143] S.H. Oliet, R. Piet, D.A. Poulain, Control of glutamate clearance and synaptic efficacy by glial coverage of neurons, Science 292(5518) (2001) 923-6.

[144] J.D. Rothstein, M. Dykes-Hoberg, C.A. Pardo, L.A. Bristol, L. Jin, R.W. Kuncl, Y. Kanai, M.A. Hediger, Y. Wang, J.P. Schielke, D.F. Welty, Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate, Neuron 16(3) (1996) 675-86. [145] A. Bellot-Saez, O. Kekesi, J.W. Morley, Y. Buskila, Astrocytic modulation of neuronal excitability through K(+) spatial buffering, Neurosci Biobehav Rev 77 (2017) 87-97.

[146] A. Araque, V. Parpura, R.P. Sanzgiri, P.G. Haydon, Tripartite synapses: glia, the unacknowledged partner, Trends Neurosci 22(5) (1999) 208-15.

[147] A. Araque, G. Carmignoto, P.G. Haydon, S.H. Oliet, R. Robitaille, A. Volterra, Gliotransmitters travel in time and space, Neuron 81(4) (2014) 728-39.

[148] M. Bsibsi, C. Persoon-Deen, R.W. Verwer, S. Meeuwsen, R. Ravid, J.M. Van Noort, Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators, Glia 53(7) (2006) 688-95.

[149] S.S. Choi, H.J. Lee, I. Lim, J. Satoh, S.U. Kim, Human astrocytes: secretome profiles of cytokines and chemokines, PLoS One 9(4) (2014) e92325.

[150] I.Y. Chung, E.N. Benveniste, Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta, J Immunol 144(8) (1990) 2999-3007.

[151] J.G. Norris, E.N. Benveniste, Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine, J Neuroimmunol 45(1-2) (1993) 137-45.

[152] R. Brambilla, V. Bracchi-Ricard, W.H. Hu, B. Frydel, A. Bramwell, S. Karmally, E.J. Green, J.R. Bethea, Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury, J Exp Med 202(1) (2005) 145-56.

[153] G. van Loo, R. De Lorenzi, H. Schmidt, M. Huth, A. Mildner, M. Schmidt-Supprian, H. Lassmann, M.R. Prinz, M. Pasparakis, Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice, Nat Immunol 7(9) (2006) 954-61.

[154] M. Eddleston, L. Mucke, Molecular profile of reactive astrocytes--implications for their role in neurologic disease, Neuroscience 54(1) (1993) 15-36.

[155] M.R. Hernandez, O.A. Agapova, P. Yang, M. Salvador-Silva, C.S. Ricard, S. Aoi, Differential gene expression in astrocytes from human normal and glaucomatous optic nerve head analyzed by cDNA microarray, Glia 38(1) (2002) 45-64.

[156] J.L. Ridet, S.K. Malhotra, A. Privat, F.H. Gage, Reactive astrocytes: cellular and molecular cues to biological function, Trends Neurosci 20(12) (1997) 570-7.

[157] M.V. Sofroniew, Molecular dissection of reactive astrogliosis and glial scar formation, Trends Neurosci 32(12) (2009) 638-47.

[158] A. Gomez-Arboledas, J.C. Davila, E. Sanchez-Mejias, V. Navarro, C. Nunez-Diaz, R. Sanchez-Varo, M.V. Sanchez-Mico, L. Trujillo-Estrada, J.J. Fernandez-Valenzuela, M. Vizuete, J.X. Comella, E. Galea, J. Vitorica, A. Gutierrez, Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease, Glia 66(3) (2018) 637-653.

[159] Y.M. Morizawa, Y. Hirayama, N. Ohno, S. Shibata, E. Shigetomi, Y. Sui, J. Nabekura, K. Sato, F. Okajima, H. Takebayashi, H. Okano, S. Koizumi, Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway, Nat Commun 8(1) (2017) 28.

[160] G. Ponath, S. Ramanan, M. Mubarak, W. Housley, S. Lee, F.R. Sahinkaya, A. Vortmeyer, C.S. Raine, D. Pitt, Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology, Brain 140(2) (2017) 399-413.

[161] N.M. Wakida, G.M.S. Cruz, C.C. Ro, E.G. Moncada, N. Khatibzadeh, L.A. Flanagan, M.W. Berns, Phagocytic response of astrocytes to damaged neighboring cells, PLoS One 13(4) (2018) e0196153.

[162] N.A. Oberheim, G.F. Tian, X. Han, W. Peng, T. Takano, B. Ransom, M. Nedergaard, Loss of astrocytic domain organization in the epileptic brain, J Neurosci 28(13) (2008) 3264-76.

[163] U. Wilhelmsson, E.A. Bushong, D.L. Price, B.L. Smarr, V. Phung, M. Terada, M.H. Ellisman, M. Pekny, Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury, Proc Natl Acad Sci U S A 103(46) (2006) 17513-8.

[164] R.R. Voskuhl, R.S. Peterson, B. Song, Y. Ao, L.B. Morales, S. Tiwari-Woodruff, M.V. Sofroniew, Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS, J Neurosci 29(37) (2009) 11511-22.

[165] N. Didier, I.A. Romero, C. Creminon, A. Wijkhuisen, J. Grassi, A. Mabondzo, Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability, J Neurochem 86(1) (2003) 246-54.

[166] G.J. Pereira, M. Antonioli, H. Hirata, R.P. Ureshino, A.R. Nascimento, C. Bincoletto, T. Vescovo, M. Piacentini, G.M. Fimia, S.S. Smaili, Glutamate induces autophagy via the two-pore channels in neural cells, Oncotarget 8(8) (2017) 12730-12740.

[167] S.M. Son, M.Y. Cha, H. Choi, S. Kang, H. Choi, M.S. Lee, S.A. Park, I. Mook-Jung, Insulindegrading enzyme secretion from astrocytes is mediated by an autophagy-based unconventional secretory pathway in Alzheimer disease, Autophagy 12(5) (2016) 784-800.

[168] S.M. Son, S. Kang, H. Choi, I. Mook-Jung, Statins induce insulin-degrading enzyme secretion from astrocytes via an autophagy-based unconventional secretory pathway, Mol Neurodegener 10 (2015) 56.

[169] C.M. Fader, M.O. Aguilera, M.I. Colombo, ATP is released from autophagic vesicles to the extracellular space in a VAMP7-dependent manner, Autophagy 8(12) (2012) 1741-56.

[170] Y. Wang, I. Martins, Y. Ma, O. Kepp, L. Galluzzi, G. Kroemer, Autophagy-dependent ATP release from dying cells via lysosomal exocytosis, Autophagy 9(10) (2013) 1624-5.

[171] Z. Zhang, G. Chen, W. Zhou, A. Song, T. Xu, Q. Luo, W. Wang, X.S. Gu, S. Duan, Regulated ATP release from astrocytes through lysosome exocytosis, Nat Cell Biol 9(8) (2007) 945-53.

[172] S. Martin, A.M. Dudek-Peric, A.D. Garg, H. Roose, S. Demirsoy, S. Van Eygen, F. Mertens, P. Vangheluwe, H. Vankelecom, P. Agostinis, An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF(V600E) inhibitor-resistant metastatic melanoma cells, Autophagy 13(9) (2017) 1512-1527.

[173] L.I. Bruijn, M.W. Becher, M.K. Lee, K.L. Anderson, N.A. Jenkins, N.G. Copeland, S.S. Sisodia, J.D. Rothstein, D.R. Borchelt, D.L. Price, D.W. Cleveland, ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions, Neuron 18(2) (1997) 327-38.

[174] E. Motori, J. Puyal, N. Toni, A. Ghanem, C. Angeloni, M. Malaguti, G. Cantelli-Forti, B. Berninger, K.K. Conzelmann, M. Gotz, K.F. Winklhofer, S. Hrelia, M. Bergami, Inflammation-induced alteration of astrocyte mitochondrial dynamics requires autophagy for mitochondrial network maintenance, Cell Metab 18(6) (2013) 844-59.

[175] C. Di Malta, J.D. Fryer, C. Settembre, A. Ballabio, Astrocyte dysfunction triggers neurodegeneration in a lysosomal storage disorder, Proc Natl Acad Sci U S A 109(35) (2012) E2334- 42.

[176] C.H. Davis, K.Y. Kim, E.A. Bushong, E.A. Mills, D. Boassa, T. Shih, M. Kinebuchi, S. Phan, Y. Zhou, N.A. Bihlmeyer, J.V. Nguyen, Y. Jin, M.H. Ellisman, N. Marsh-Armstrong, Transcellular degradation of axonal mitochondria, Proc Natl Acad Sci U S A 111(26) (2014) 9633-8.

[177] I. Melentijevic, M.L. Toth, M.L. Arnold, R.J. Guasp, G. Harinath, K.C. Nguyen, D. Taub, J.A. Parker, C. Neri, C.V. Gabel, D.H. Hall, M. Driscoll, C. elegans neurons jettison protein aggregates and mitochondria under neurotoxic stress, Nature 542(7641) (2017) 367-371.

[178] D.K. Hartline, D.R. Colman, Rapid conduction and the evolution of giant axons and myelinated fibers, Curr Biol 17(1) (2007) R29-35.

[179] A.I. Boullerne, The history of myelin, Exp Neurol 283(Pt B) (2016) 431-45.

[180] A. Peters, Observations on the Connexions between Myelin Sheaths and Glial Cells in the Optic Nerves of Young Rats, J Anat 98 (1964) 125-34.

[181] N. Snaidero, W. Mobius, T. Czopka, L.H. Hekking, C. Mathisen, D. Verkleij, S. Goebbels, J. Edgar, D. Merkler, D.A. Lyons, K.A. Nave, M. Simons, Myelin membrane wrapping of CNS axons by PI(3,4,5)P3-dependent polarized growth at the inner tongue, Cell 156(1-2) (2014) 277-90.

[182] N. Snaidero, C. Velte, M. Myllykoski, A. Raasakka, A. Ignatev, H.B. Werner, M.S. Erwig, W. Mobius, P. Kursula, K.A. Nave, M. Simons, Antagonistic Functions of MBP and CNP Establish Cytosolic Channels in CNS Myelin, Cell Rep 18(2) (2017) 314-323.

[183] U. Funfschilling, L.M. Supplie, D. Mahad, S. Boretius, A.S. Saab, J. Edgar, B.G. Brinkmann, C.M. Kassmann, I.D. Tzvetanova, W. Mobius, F. Diaz, D. Meijer, U. Suter, B. Hamprecht, M.W. Sereda, C.T. Moraes, J. Frahm, S. Goebbels, K.A. Nave, Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity, Nature 485(7399) (2012) 517-21.

[184] Y. Lee, B.M. Morrison, Y. Li, S. Lengacher, M.H. Farah, P.N. Hoffman, Y. Liu, A. Tsingalia, L. Jin, P.W. Zhang, L. Pellerin, P.J. Magistretti, J.D. Rothstein, Oligodendroglia metabolically support axons and contribute to neurodegeneration, Nature 487(7408) (2012) 443-8.

[185] A.S. Saab, I.D. Tzvetavona, A. Trevisiol, S. Baltan, P. Dibaj, K. Kusch, W. Mobius, B. Goetze, H.M. Jahn, W. Huang, H. Steffens, E.D. Schomburg, A. Perez-Samartin, F. Perez-Cerda, D. Bakhtiari, C. Matute, S. Lowel, C. Griesinger, J. Hirrlinger, F. Kirchhoff, K.A. Nave, Oligodendroglial NMDA Receptors Regulate Glucose Import and Axonal Energy Metabolism, Neuron 91(1) (2016) 119-32. [186] K. Pukass, O. Goldbaum, C. Richter-Landsberg, Mitochondrial impairment and oxidative stress compromise autophagosomal degradation of alpha-synuclein in oligodendroglial cells, J Neurochem 135(1) (2015) 194-205.

[187] M. Riedel, O. Goldbaum, L. Schwarz, S. Schmitt, C. Richter-Landsberg, 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy, PLoS One 5(1) (2010) e8753.

[188] M. Noack, C. Richter-Landsberg, Activation of autophagy by rapamycin does not protect oligodendrocytes against protein aggregate formation and cell death induced by proteasomal inhibition, J Mol Neurosci 55(1) (2015) 99-108.

[189] C.M. Smith, J.A. Mayer, I.D. Duncan, Autophagy promotes oligodendrocyte survival and function following dysmyelination in a long-lived myelin mutant, J Neurosci 33(18) (2013) 8088-100.

[190] S. Saraswat Ohri, A.N. Bankston, S.A. Mullins, Y. Liu, K.R. Andres, J.E. Beare, R.M. Howard, D.A. Burke, A.S. Riegler, A.E. Smith, M. Hetman, S.R. Whittemore, Blocking Autophagy in Oligodendrocytes Limits Functional Recovery after Spinal Cord Injury, J Neurosci 38(26) (2018) 5900- 5912.

[191] J.A. Gomez-Sanchez, L. Carty, M. Iruarrizaga-Lejarreta, M. Palomo-Irigoven, M. Varela-Rev. M. Griffith, J. Hantke, N. Macias-Camara, M. Azkargorta, I. Aurrekoetxea, V.G. De Juan, H.B. Jefferies, P. Aspichueta, F. Elortza, A.M. Aransay, M.L. Martinez-Chantar, F. Baas, J.M. Mato, R. Mirsky, A. Woodhoo, K.R. Jessen, Schwann cell autophagy, myelinophagy, initiates myelin clearance from injured nerves, J Cell Biol 210(1) (2015) 153-68.

[192] N. Chen, L. Dai, Y. Jiang, J. Wang, H. Hao, Y. Ren, X. Leng, L. Zang, Y. Wu, Endoplasmic reticulum stress intolerance in EIF2B3 mutant oligodendrocytes is modulated by depressed autophagy, Brain Dev 38(5) (2016) 507-15.

[193] S. Roy, A.M. Leidal, J. Ye, S.M. Ronen, J. Debnath, Autophagy-Dependent Shuttling of TBC1D5 Controls Plasma Membrane Translocation of GLUT1 and Glucose Uptake, Mol Cell 67(1) (2017) 84- 95 e5.

[194] I.R. Mackenzie, O. Ansorge, M. Strong, J. Bilbao, L. Zinman, L.C. Ang, M. Baker, H. Stewart, A. Eisen, R. Rademakers, M. Neumann, Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation, Acta Neuropathol 122(1) (2011) 87-98.

[195] I.R. Mackenzie, E.H. Bigio, P.G. Ince, F. Geser, M. Neumann, N.J. Cairns, L.K. Kwong, M.S. Forman, J. Ravits, H. Stewart, A. Eisen, L. McClusky, H.A. Kretzschmar, C.M. Monoranu, J.R. Highley, J. Kirby, T. Siddique, P.J. Shaw, V.M. Lee, J.Q. Trojanowski, Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations, Ann Neurol 61(5) (2007) 427-34.

[196] D. Seilhean, C. Cazeneuve, V. Thuries, O. Russaouen, S. Millecamps, F. Salachas. V. Meininger, E. Leguern, C. Duyckaerts, Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation, Acta Neuropathol 118(4) (2009) 561-73.

[197] H. Ilieva, M. Polymenidou, D.W. Cleveland, Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond, J Cell Biol 187(6) (2009) 761-72.

[198] S. Boillee, K. Yamanaka, C.S. Lobsiger, N.G. Copeland, N.A. Jenkins, G. Kassiotis, G. Kollias, D.W. Cleveland, Onset and progression in inherited ALS determined by motor neurons and microglia, Science 312(5778) (2006) 1389-92.

[199] J. Cady, E.D. Koval, B.A. Benitez, C. Zaidman, J. Jockel-Balsarotti, P. Allred, R.H. Baloh, J. Ravits, E. Simpson, S.H. Appel, A. Pestronk, A.M. Goate, T.M. Miller, C. Cruchaga, M.B. Harms, TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis, JAMA Neurol 71(4) (2014) 449-53.

[200] B. Levine, N. Mizushima, H.W. Virgin, Autophagy in immunity and inflammation, Nature 469(7330) (2011) 323-35.

